Cite
Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
MLA
Willis, Sophie E., et al. “Retrospective Analysis of Schlafen11 (SLFN11) to Predict the Outcomes to Therapies Affecting the DNA Damage Response.” British Journal of Cancer, vol. 125, no. 12, Dec. 2021, pp. 1666–76. EBSCOhost, https://doi.org/10.1038/s41416-021-01560-1.
APA
Willis, S. E., Winkler, C., Roudier, M. P., Baird, T., Marco-Casanova, P., Jones, E. V., Rowe, P., Rodriguez-Canales, J., Angell, H. K., Ng, F. S. L., Waring, P. M., Hodgson, D., Ledermann, J. A., Weberpals, J. I., Dean, E., Harrington, E. A., Barrett, J. C., Pierce, A. J., Leo, E., & Jones, G. N. (2021). Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. British Journal of Cancer, 125(12), 1666–1676. https://doi.org/10.1038/s41416-021-01560-1
Chicago
Willis, Sophie E., Claudia Winkler, Martine P. Roudier, Tarrion Baird, Paola Marco-Casanova, Emma V. Jones, Philip Rowe, et al. 2021. “Retrospective Analysis of Schlafen11 (SLFN11) to Predict the Outcomes to Therapies Affecting the DNA Damage Response.” British Journal of Cancer 125 (12): 1666–76. doi:10.1038/s41416-021-01560-1.